From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI

Drug development productivity has not improved despite five decades of computational advancement, with the probability that a compound entering Phase I achieving regulatory approval remaining near 10%. Each automation wave increased throughput while leaving the interpretive bottleneck intact; scientists continued to formulate questions, evaluate outputs, and make advancement decisions regardless of how fast data accumulated upstream. Agentic AI systems capable of reasoning, planning, and executing multi-step analyses without continuous human instruction represent the first class of ubiquitous computational tools with the architectural potential to compress this bottleneck, but the implications extend beyond efficiency. As computational systems begin to perform interpretation, execution, and evaluation steps that previously required human judgment, the scientist's contribution shifts from conducting analyses to specifying objectives precise enough for autonomous execution and evaluating recommendations that may be difficult to verify independently. Whether this shift improves aggregate productivity depends on whether autonomous systems address the fundamental causes of clinical failure, including insufficient efficacy, inadequate safety prediction, and poor preclinical translation, rather than merely accelerating the analytical work surrounding them. This review examines what clinical pharmacology scientists must become as these systems enter routine practice. The competencies required for effective orchestration differ from those emphasized in traditional pharmaceutical training, and existing governance structures do not address the failure modes that accompany delegation of scientific judgment to autonomous systems. Whether this shift improves productivity or introduces new failure modes depends on governance and training investments that the field has not yet made.